BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma

British Journal of Dermatology

Volumn 172, Issue 4, 2015, Pages 1128-1131

  Garcia Casado Z ^a   Traves, V ^a   Banuls J ^b   Niveiro, M ^b   Gimeno Carpio, E ^c   Jimenez Sanchez, A I ^c   Moragon M ^d   Onrubia, J A ^d   Oliver, V ^e   Kumar, R ^f   Nagore, E ^a,g  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d Hospital Universitario San Joan   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; MC1R PROTEIN; PROTEIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MELANOCORTIN 1 RECEPTOR; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ADULT; CANCER LOCALIZATION; CHRONIC SUN DAMAGE; CLINICAL FEATURE; CUTANEOUS MELANOMA; DNA SEQUENCE; EPITHELIOID CELL; FEMALE; GENE MUTATION; GENOTYPE; HAIR COLOR; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MELANOMA; ONCOGENE N RAS; PRIORITY JOURNAL; SKIN DEFECT; SUN EXPOSURE; AGED; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROSPECTIVE STUDY; SKIN TUMOR;

AGED; FEMALE; GENOTYPE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, MELANOCORTIN, TYPE 1; SKIN NEOPLASMS;

EID: 84926149735     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13521     Document Type: Letter

References (12)

1. Whiteman DC, Watt P, Purdie DM, et al,. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95: 806-12.
2. Olsen CM, Zens MS, Stukel TA, et al,. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer 2009; 124: 937-44.
3. Lee JH, Choi JW, Kim YS,. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011; 164: 776-84.
4. Edlundh-Rose E, Egyházi S, Omholt K, et al,. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16: 471-8.
5. Landi MT, Bauer J, Pfeiffer RM, et al,. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006; 313: 521-2.
6. Bauer J, Büttner P, Murali R, et al,. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24: 345-51.
7. Fargnoli MC, Pike K, Pfeiffer RM, et al,. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol 2008; 128: 2485-90.
8. Scherer D, Rachakonda PS, Angelini S, et al,. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors. J Invest Dermatol 2010; 130: 2844-8.
9. Hacker E, Hayward NK, Dumenil T, et al,. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol 2009; 130: 241-8.
10. Thomas NE, Kanetsky PA, Edmiston SN, et al,. Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study. J Invest Dermatol 2010; 130: 1463-5.
11. Hacker E, Nagore E, Cerroni L, et al,. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations. J Invest Dermatol 2013; 133: 1027-33.
12. Ellerhorst JA, Greene VR, Ekmekcioglu S, et al,. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2010; 17: 229-35.